Qiagen to acquire Parse Biosciences

QIAGEN has announced its plans to acquire Parse Biosciences, a rapidly growing company known for its instrument-free single-cell technology. Parse’s Evercode platform enables highly scalable single-cell analysis, processing millions of cells without specialized equipment, and is already in use in thousands of laboratories worldwide.

With this acquisition, QIAGEN expands its portfolio of sample technologies and strengthens its presence in the field of single-cell genomics. Parse’s scalable chemistry is also expected to accelerate growth in the QIAGEN Digital Insights (QDI) bioinformatics business, enabling customers to generate, process and interpret AI-driven single-cell data more efficiently and at much greater scale, from the first sample to actionable insights. The agreement is expected to close by the end of 2025 and will allow QIAGEN to offer more integrated and accessible workflows for large-scale single-cell research.

Qiagen acquires Parse Biosciences

Read more:

https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2025/QIAGEN-to-acquire-Parse-Biosciences-expanding-its-Sample-technologies-portfolio-into-highly-scalable-single-cell-solutions/default.aspx

https://www.parsebiosciences.com/news/parse-biosciences-is-joining-qiagen/